Neetu Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Neetu Singh has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Archana Mishra
Department of Surgery, King George's Medical University, Lucknow 226003, India
5 shared publicationsDinesh Kumar Sahu
Molecular Biology Lab, Department of Centre for Advanced Research, King George's Medical University, Lucknow 226003, India
4 shared publications- Hari Shyam
Mehrotra Pathology Pvt. Ltd, Lucknow, Uttar Pradesh, India
4 shared publications Madan Lal Brahma Bhatt
Department of Radiotherapy, King George's Medical University, Lucknow, India
4 shared publicationsNawazish Alam
Molecular Biology Lab, Department of Centre for Advanced Research, King George's Medical University, Lucknow 226003, India
4 shared publicationsPratap Shankar
Molecular Biology Lab, Department of Centre for Advanced Research, King George's Medical University, Lucknow 226003, India
4 shared publications
Latest Publications
- Open Access
- 11 May 2026
- Published by IntechOpen
Repurposing AMACR as a Precision Metabolic Target in Castration-Resistant Prostate Cancer
Alpha-methylacyl-CoA racemase (AMACR; P504S) is a peroxisomal and mitochondrial enzyme consistently overexpressed in prostate adenocarcinoma and widely used as a diagnostic biomarker. In this chapter, AMACR is reframed as a functionally relevant metabolic regulator and precision therapeutic target rather than merely a passive diagnostic marker. Evidence indicates that AMACR mRNA is elevated more than 600-fold in prostate cancer relative to benign epithelium, with significantly higher expression in androgen-independent C4-2 cells compared with androgen-dependent LNCaP cells. Notably, AMACR knockdown restores androgen sensitivity through androgen receptor upregulation and suppression of insulin-like growth factor 1 (IGF1) and platelet-derived growth factor A (PDGFA), converting hormone-independent growth to hormone-dependent proliferation. This chapter integrates AMACR enzymology, splice variant biology, promoter regulation, peroxisomal signalling, peroxisome proliferator-activated receptor (PPAR)-mediated transcriptional feedback, and RNA interference strategies. Particular emphasis is placed on transcript IA, the predominant catalytically active isoform, as a rational focal point for isoform-specific intervention. We propose a disease-orientated repurposing framework that transforms a diagnostic biomarker into a clinically actionable metabolic vulnerability in CRPC. Targeting metabolic enzymes that sustain castration-resistant growth represents an emerging paradigm in precision oncology and offers promising avenues for next-generation therapeutic development. β generates acetyl- and branched- acyl-species activating PPAR isoforms (α, γ, δ). Dual PPARγ signalling: anti-tumourigenic (differentiation, EMT suppression) and pro-tumourigenic (AKT3 activation, PGC1α retention, ATP production). An immune axis engages CD8⁺ T-survival (PPARα) and tBreg-mediated immunosuppression (leukotriene B₄). Data drawn from Refs. [9, 10, 17]. Figure created by the author; all component data sourced from cited primary literature.
- 11 May 2026
- Published by IntechOpen
Open AccessRepurposing AMACR as a Precision Metabolic Target in Castration-Resistant Prostate Cancer
Alpha-methylacyl-CoA racemase (AMACR; P504S) is a peroxisomal and mitochondrial enzyme consistently overexpressed in prostate adenocarcinoma and widely used as a diagnostic biomarker. In this chapter, AMACR is reframed as a functionally relevant metabolic regulator and precision therapeutic target rather than merely a passive diagnostic marker. Evidence indicates that AMACR mRNA is elevated more than 600-fold in prostate cancer relative to benign epithelium, with significantly higher expression in androgen-independent C4-2 cells compared with androgen-dependent LNCaP cells. Notably, AMACR knockdown restores androgen sensitivity through androgen receptor upregulation and suppression of insulin-like growth factor 1 (IGF1) and platelet-derived growth factor A (PDGFA), converting hormone-independent growth to hormone-dependent proliferation. This chapter integrates AMACR enzymology, splice variant biology, promoter regulation, peroxisomal signalling, peroxisome proliferator-activated receptor (PPAR)-mediated transcriptional feedback, and RNA interference strategies. Particular emphasis is placed on transcript IA, the predominant catalytically active isoform, as a rational focal point for isoform-specific intervention. We propose a disease-orientated repurposing framework that transforms a diagnostic biomarker into a clinically actionable metabolic vulnerability in CRPC. Targeting metabolic enzymes that sustain castration-resistant growth represents an emerging paradigm in precision oncology and offers promising avenues for next-generation therapeutic development. β generates acetyl- and branched- acyl-species activating PPAR isoforms (α, γ, δ). Dual PPARγ signalling: anti-tumourigenic (differentiation, EMT suppression) and pro-tumourigenic (AKT3 activation, PGC1α retention, ATP production). An immune axis engages CD8⁺ T-survival (PPARα) and tBreg-mediated immunosuppression (leukotriene B₄). Data drawn from Refs. [9, 10, 17]. Figure created by the author; all component data sourced from cited primary literature.
- 17 April 2026
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
RNA surveillance failure as a determinant of hypoxic immune escape and metastatic tumour state
Metastasis remains the dominant cause of cancer mortality, yet genetic alteration alone fails to explain the spatial plasticity, immune escape, and therapy resistance characteristic of advanced solid tumours. Here we advance an RNA-centric framework in which exon-mediated activation of transcription starts (EMATS) amplifies transcriptional output, while hierarchical RNA surveillance—nuclear decay and cytoplasmic nonsense-mediated decay (NMD)—determines transcript fate downstream of transcription. In hypoxic tumour cores, EMATS-driven RNA overproduction overwhelms surveillance capacity, causing RNA fate collapse, proteostasis stress, destabilisation of proteasome–HLA coupling, and immune invisibility. In contrast, invasive tumour margins preserve RNA surveillance, maintaining antigen presentation and metastatic signalling. This framework explains immune escape independently of mutation burden or cytokine excess. It reconciles paradoxes in immunotherapy response, and positions RNA fate as a tractable axis for biomarker development and therapeutic stratification.
- 17 April 2026
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
RNA surveillance failure as a determinant of hypoxic immune escape and metastatic tumour state
Metastasis remains the dominant cause of cancer mortality, yet genetic alteration alone fails to explain the spatial plasticity, immune escape, and therapy resistance characteristic of advanced solid tumours. Here we advance an RNA-centric framework in which exon-mediated activation of transcription starts (EMATS) amplifies transcriptional output, while hierarchical RNA surveillance—nuclear decay and cytoplasmic nonsense-mediated decay (NMD)—determines transcript fate downstream of transcription. In hypoxic tumour cores, EMATS-driven RNA overproduction overwhelms surveillance capacity, causing RNA fate collapse, proteostasis stress, destabilisation of proteasome–HLA coupling, and immune invisibility. In contrast, invasive tumour margins preserve RNA surveillance, maintaining antigen presentation and metastatic signalling. This framework explains immune escape independently of mutation burden or cytokine excess. It reconciles paradoxes in immunotherapy response, and positions RNA fate as a tractable axis for biomarker development and therapeutic stratification.
- Open Access
- 13 April 2026
- Published by Frontiers Media SA in Frontiers in Thermal Engineering
- Vol. 6, 1798897
Advanced computational approaches for bioheat transfer in minimally invasive cancer thermal therapies
Minimally invasive thermal therapies—including radiofrequency ablation, microwave ablation, laser interstitial thermal therapy, and high-intensity focused ultrasound—are increasingly central to the local treatment of solid tumors across multiple organ systems. The efficacy and safety of these modalities depend critically on accurate prediction of spatiotemporal temperature distributions within biologically complex tissues characterized by structural heterogeneity, vascular perfusion, and dynamic thermophysiological responses. Although classical bioheat models have provided a foundational theoretical framework, their simplifying assumptions frequently limit predictive fidelity under clinically realistic, perfusion-dominated, and high-gradient conditions. This Advanced Review synthesizes recent advances in computational bioheat transfer modeling for cancer thermal therapies, encompassing extended and non-Fourier formulations, multiphysics and multiscale frameworks, vascular-resolved and porous-media approaches, patient-specific image-based simulations, and emerging hybrid data-driven strategies. Quantitative comparisons across modeling paradigms are presented to clarify trade-offs among physiological fidelity, computational tractability, and validation maturity. Particular emphasis is placed on vascular heat transport, temperature-dependent thermophysical properties, phase transition phenomena, and thermal damage kinetics, including Arrhenius-based injury modeling. The review further examines validation hierarchies, uncertainty quantification, regulatory credibility frameworks, and the growing integration of physics-informed machine learning for real-time treatment planning and adaptive control. Collectively, these developments signal a transition toward precision, uncertainty-aware, and patient-adaptive thermal oncology, while highlighting the methodological, computational, and regulatory challenges that must be addressed to enable routine clinical translation.
- 13 April 2026
- Published by Frontiers Media SA in Frontiers in Thermal Engineering
- Vol. 6, 1798897
Open AccessAdvanced computational approaches for bioheat transfer in minimally invasive cancer thermal therapies
Minimally invasive thermal therapies—including radiofrequency ablation, microwave ablation, laser interstitial thermal therapy, and high-intensity focused ultrasound—are increasingly central to the local treatment of solid tumors across multiple organ systems. The efficacy and safety of these modalities depend critically on accurate prediction of spatiotemporal temperature distributions within biologically complex tissues characterized by structural heterogeneity, vascular perfusion, and dynamic thermophysiological responses. Although classical bioheat models have provided a foundational theoretical framework, their simplifying assumptions frequently limit predictive fidelity under clinically realistic, perfusion-dominated, and high-gradient conditions. This Advanced Review synthesizes recent advances in computational bioheat transfer modeling for cancer thermal therapies, encompassing extended and non-Fourier formulations, multiphysics and multiscale frameworks, vascular-resolved and porous-media approaches, patient-specific image-based simulations, and emerging hybrid data-driven strategies. Quantitative comparisons across modeling paradigms are presented to clarify trade-offs among physiological fidelity, computational tractability, and validation maturity. Particular emphasis is placed on vascular heat transport, temperature-dependent thermophysical properties, phase transition phenomena, and thermal damage kinetics, including Arrhenius-based injury modeling. The review further examines validation hierarchies, uncertainty quantification, regulatory credibility frameworks, and the growing integration of physics-informed machine learning for real-time treatment planning and adaptive control. Collectively, these developments signal a transition toward precision, uncertainty-aware, and patient-adaptive thermal oncology, while highlighting the methodological, computational, and regulatory challenges that must be addressed to enable routine clinical translation.
- 10 April 2026
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 119 (8) , 591-596
Pre-mRNA splicing and cancer: exon-mediated transcriptional amplification as an emerging hallmark of malignancy
Cancer progression is commonly interpreted through genetic mutation and clonal selection. While this framework explains many aspects of tumour initiation, it does not fully account for prolonged dormancy, late relapse, spatial heterogeneity, or metastasis occurring without new driver mutations. Increasing evidence indicates that these behaviours are governed by reversible regulatory processes operating downstream of DNA sequence. Here, we advance an RNA-centric framework in which transcriptional reinforcement and RNA fate control jointly shape tumour evolution across time and space. We focus on exon-mediated activation of transcription starts (EMATS), a mechanism whereby efficient exon recognition stabilises promoter-proximal RNA polymerase II, suppresses premature termination, and amplifies transcription from weak or context-dependent promoters without requiring promoter mutation, enhancer rewiring, or immediate protein output. The resulting transcripts are subsequently filtered through RNA fate checkpoints that determine nuclear retention, decay, or persistence, uncoupling transcriptional activity from translation. Within this model, non-coding and non-canonical RNAs function as spatiotemporal reporters of tumour state, encoding when and where transcriptional programmes are engaged. RNA persistence enables tumour cells to remain transcriptionally primed under hypoxia, therapeutic pressure, or immune surveillance, supporting dormancy and rapid reactivation. By reframing tumour evolution as RNA state regulation, this framework provides a mechanistic basis for plasticity, relapse, and therapy resistance, and highlights RNA states as clinically actionable biomarkers and vulnerabilities.
- 10 April 2026
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 119 (8) , 591-596
Pre-mRNA splicing and cancer: exon-mediated transcriptional amplification as an emerging hallmark of malignancy
Cancer progression is commonly interpreted through genetic mutation and clonal selection. While this framework explains many aspects of tumour initiation, it does not fully account for prolonged dormancy, late relapse, spatial heterogeneity, or metastasis occurring without new driver mutations. Increasing evidence indicates that these behaviours are governed by reversible regulatory processes operating downstream of DNA sequence. Here, we advance an RNA-centric framework in which transcriptional reinforcement and RNA fate control jointly shape tumour evolution across time and space. We focus on exon-mediated activation of transcription starts (EMATS), a mechanism whereby efficient exon recognition stabilises promoter-proximal RNA polymerase II, suppresses premature termination, and amplifies transcription from weak or context-dependent promoters without requiring promoter mutation, enhancer rewiring, or immediate protein output. The resulting transcripts are subsequently filtered through RNA fate checkpoints that determine nuclear retention, decay, or persistence, uncoupling transcriptional activity from translation. Within this model, non-coding and non-canonical RNAs function as spatiotemporal reporters of tumour state, encoding when and where transcriptional programmes are engaged. RNA persistence enables tumour cells to remain transcriptionally primed under hypoxia, therapeutic pressure, or immune surveillance, supporting dormancy and rapid reactivation. By reframing tumour evolution as RNA state regulation, this framework provides a mechanistic basis for plasticity, relapse, and therapy resistance, and highlights RNA states as clinically actionable biomarkers and vulnerabilities.
- 3 April 2026
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
RNA-Centric Tumour Evolution: Transcriptional Reinforcement, Reversibility, and Clinical Plasticity Beyond Genetics
Cancer progression is traditionally interpreted through genetic mutation and clonal selection. While this framework explains tumour initiation, it does not fully account for prolonged dormancy, late relapse, spatial heterogeneity, or metastasis occurring without new driver mutations. Increasing evidence instead implicates reversible regulatory layers operating downstream of DNA sequence. We propose an RNA-centric framework in which transcriptional reinforcement and RNA fate control jointly shape tumour evolution across time and space. Weak or context-dependent promoters—common in cancer—can generate sustained transcriptional output through exon-dependent reinforcement without promoter mutation, enhancer hijacking, or immediate protein production. The resulting RNA output is then filtered through RNA fate checkpoints that govern decay, nuclear retention, export, or persistence, functionally uncoupling transcription from translation. Within this model, non-coding and non-canonical RNAs act as spatiotemporal reporters of tumour state, reflecting when and where transcriptional programmes are engaged rather than which proteins are produced. RNA persistence enables tumours to remain transcriptionally primed under hypoxia, therapy, or immune pressure, supporting dormancy and rapid reactivation without irreversible genetic change. Reframing tumour evolution around RNA state regulation provides a coherent explanation for relapse and resistance and highlights RNA states as clinically tractable biomarkers and therapeutic targets that complement DNA-based oncology.
- 3 April 2026
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
RNA-Centric Tumour Evolution: Transcriptional Reinforcement, Reversibility, and Clinical Plasticity Beyond Genetics
Cancer progression is traditionally interpreted through genetic mutation and clonal selection. While this framework explains tumour initiation, it does not fully account for prolonged dormancy, late relapse, spatial heterogeneity, or metastasis occurring without new driver mutations. Increasing evidence instead implicates reversible regulatory layers operating downstream of DNA sequence. We propose an RNA-centric framework in which transcriptional reinforcement and RNA fate control jointly shape tumour evolution across time and space. Weak or context-dependent promoters—common in cancer—can generate sustained transcriptional output through exon-dependent reinforcement without promoter mutation, enhancer hijacking, or immediate protein production. The resulting RNA output is then filtered through RNA fate checkpoints that govern decay, nuclear retention, export, or persistence, functionally uncoupling transcription from translation. Within this model, non-coding and non-canonical RNAs act as spatiotemporal reporters of tumour state, reflecting when and where transcriptional programmes are engaged rather than which proteins are produced. RNA persistence enables tumours to remain transcriptionally primed under hypoxia, therapy, or immune pressure, supporting dormancy and rapid reactivation without irreversible genetic change. Reframing tumour evolution around RNA state regulation provides a coherent explanation for relapse and resistance and highlights RNA states as clinically tractable biomarkers and therapeutic targets that complement DNA-based oncology.
- Open Access
- 20 April 2024
- Published by Korean Cleft Palate-Craniofacial Association in Archives of Craniofacial Surgery
- Vol. 25 (2) , 51-61
An intercontinental comparison of the influence of smoking on the occurrence of nonsyndromic cleft lip and palate: a meta-analysis and systematic review
Background: The influence of smoking on nonsyndromic clefts has been a topic of research for many years. However, few studies have investigated the effect of smoking on causing clefts in different gene pools.Methods: A meta-analysis was conducted of case-control studies related to smoking. Keywords such as “clefts,” “cleft lip,” “cleft palate,” “orofacial cleft,” and “smoking” were used to search the MEDLINE, Embase, and Cochrane databases.Results: In total, 51 articles were reviewed. The RevMan software was utilized for the analysis, and the Mantel-Haenszel method was employed to pool the odds ratios (ORs) and 95% confidence intervals. Although the overall OR, a measure of the association between exposure and outcome, was higher for smokers than for non-smokers, this association was significantly stronger in individuals from Asia and South America (1.73), and lowest in Europe (1.31). Among active and passive smokers in Asia, the OR was approximately 0.93, indicating an equivalent impact from both types of smoking.Conclusion: This analysis indirectly suggests that restriction measures targeting both active and passive smoking are crucial in Asia.
- 20 April 2024
- Published by Korean Cleft Palate-Craniofacial Association in Archives of Craniofacial Surgery
- Vol. 25 (2) , 51-61
Open AccessAn intercontinental comparison of the influence of smoking on the occurrence of nonsyndromic cleft lip and palate: a meta-analysis and systematic review
Background: The influence of smoking on nonsyndromic clefts has been a topic of research for many years. However, few studies have investigated the effect of smoking on causing clefts in different gene pools.Methods: A meta-analysis was conducted of case-control studies related to smoking. Keywords such as “clefts,” “cleft lip,” “cleft palate,” “orofacial cleft,” and “smoking” were used to search the MEDLINE, Embase, and Cochrane databases.Results: In total, 51 articles were reviewed. The RevMan software was utilized for the analysis, and the Mantel-Haenszel method was employed to pool the odds ratios (ORs) and 95% confidence intervals. Although the overall OR, a measure of the association between exposure and outcome, was higher for smokers than for non-smokers, this association was significantly stronger in individuals from Asia and South America (1.73), and lowest in Europe (1.31). Among active and passive smokers in Asia, the OR was approximately 0.93, indicating an equivalent impact from both types of smoking.Conclusion: This analysis indirectly suggests that restriction measures targeting both active and passive smoking are crucial in Asia.
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (5_Suppleme) , A032
Abstract A032: Targeting RAS beyond KRAS, a review
RAS proteins belong to the family of GTPases and plays instrumental role in cellular growth and proliferation and dysregulation of RAS signalling is one of the key drivers of tumorigenesis. The RAS protein has four isoforms namely KRAS4A, KRAS4B, NRAS and HRAS with amino acid codons 12, 13 and 61 as common hotspots for RAS mutations. Each of these hotspot mutations appears across several cancer types, however each of them have been noted to have specific distribution across different tissues. For example, mutations in codon 12 of KRAS are most common in pancreatic, lung and colorectal cancer, NRAS mutations affecting Q61 and G12 are most prevalent in melanoma and haematological malignancies, respectively, and HRAS mutations are more frequently altered in thyroid, bladder and head and neck cancers. Substantial efforts have been made to develop small molecule inhibitors targeting KRASG12C, with demonstrated success in clinic. Early success with KRASG12C has prompted researchers targeting other RAS isoforms, such as H-RAS and N-RAS to address RAS mutated cancer burden. Discovery of pan-RAS monobody that binds to all RAS isoforms have opened new opportunities. Development of small molecule inhibitors of RAS membrane association is gaining potential as a therapeutic strategy to curb RAS signalling; Lonafarnib and Tipifarnib, inhibitors of farnesyltransferase that lipidate Ras to facilitate membrane localization, have shown effectiveness in HRAS mutated cancers and are in active clinical evaluation. Although the lack of a hydrophobic binding pocket in NRAS poses challenges to drug targeting, specific strategies such as amphiphile-mediated depalmitoylation to target the post-translational modification of NRAS and reduce its activity are being investigated. The wide variety of approaches to target the RAS signalling pathway, beyond KRAS, have resulted in a broadening patent landscape. While finding ways to specifically target RAS mutants remains a daunting challenge, herculean efforts to make clinically useful RAS-targeted drugs are beginning to provide a bounty of weapons to fight against RAS-driven tumors. Citation Format: Neetu Singh, Darren R. Tyson, Partha Pratim Sarma, Sathish Katike, Prashant K. Bhavar, Uday Kumar Surampudi. Targeting RAS beyond KRAS, a review [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr A032.
- 1 May 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (5_Suppleme) , A032
Open AccessAbstract A032: Targeting RAS beyond KRAS, a review
RAS proteins belong to the family of GTPases and plays instrumental role in cellular growth and proliferation and dysregulation of RAS signalling is one of the key drivers of tumorigenesis. The RAS protein has four isoforms namely KRAS4A, KRAS4B, NRAS and HRAS with amino acid codons 12, 13 and 61 as common hotspots for RAS mutations. Each of these hotspot mutations appears across several cancer types, however each of them have been noted to have specific distribution across different tissues. For example, mutations in codon 12 of KRAS are most common in pancreatic, lung and colorectal cancer, NRAS mutations affecting Q61 and G12 are most prevalent in melanoma and haematological malignancies, respectively, and HRAS mutations are more frequently altered in thyroid, bladder and head and neck cancers. Substantial efforts have been made to develop small molecule inhibitors targeting KRASG12C, with demonstrated success in clinic. Early success with KRASG12C has prompted researchers targeting other RAS isoforms, such as H-RAS and N-RAS to address RAS mutated cancer burden. Discovery of pan-RAS monobody that binds to all RAS isoforms have opened new opportunities. Development of small molecule inhibitors of RAS membrane association is gaining potential as a therapeutic strategy to curb RAS signalling; Lonafarnib and Tipifarnib, inhibitors of farnesyltransferase that lipidate Ras to facilitate membrane localization, have shown effectiveness in HRAS mutated cancers and are in active clinical evaluation. Although the lack of a hydrophobic binding pocket in NRAS poses challenges to drug targeting, specific strategies such as amphiphile-mediated depalmitoylation to target the post-translational modification of NRAS and reduce its activity are being investigated. The wide variety of approaches to target the RAS signalling pathway, beyond KRAS, have resulted in a broadening patent landscape. While finding ways to specifically target RAS mutants remains a daunting challenge, herculean efforts to make clinically useful RAS-targeted drugs are beginning to provide a bounty of weapons to fight against RAS-driven tumors. Citation Format: Neetu Singh, Darren R. Tyson, Partha Pratim Sarma, Sathish Katike, Prashant K. Bhavar, Uday Kumar Surampudi. Targeting RAS beyond KRAS, a review [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr A032.
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (5_Suppleme) , B036
Abstract B036: Treatment modalities in KRAS-driven cancer
KRAS is the most common RAS isoform, found to be altered in 22% of RAS-mutated cancers. The mutant protein is found most prevalently in pancreatic cancer followed by colorectal, non-small cell lung cancer and other solid tumors. Due to its structural complexity, KRAS remained “undruggable” for several decades. Recently, the discovery of a specific protein binding pocket has led to the development of small molecule inhibitors that potently bind and inhibit KRAS downstream signalling. The accelerated FDA approval of sotorasib and adagrasib for treatment of NSCLC patients harbouring KRASG12C-mutation and further clinical evaluation of several other inhibitors of KRASG12C are under investigation, however emergence of resistance and limited efficacy beyond non-small cell lung cancer is a major concern. Targeting KRAS mutations other than KRASG12C (i.e., without a mutant-specific cysteine residue) with small molecules, has been considered much more challenging, especially for developing covalent inhibitors. Small molecule targeting of KRASG12D (e.g. MRTX1133), is under active preclinical investigation and small molecule drugs that target other KRAS-activating mutations (G12S, G12R and G12V) are being intensely explored. A variety of novel alternative approaches are also being investigated to target tumors driven by mutant KRAS, such as (i) targeting complementary signalling pathways (ii) enhancing mutant KRAS protein degradation using PROTACS, (iii) developing pan-KRAS small molecules inhibitors, (iv) anti-KRAS immune cell-based therapies, (v) small interfering RNAs to block mutant KRAS expression and (vi) anti-KRAS vaccines. Here, we aim to provide a comprehensive overview of current status and future prospect of these modalities, in the context of RAS-mutated cancers. Citation Format: Darren R. Tyson, Neetu Singh, Prashant K. Bhavar, Partha Pratim Sarma, Uday Kumar Surampudi, Sathish Katike. Treatment modalities in KRAS-driven cancer [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr B036.
- 1 May 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (5_Suppleme) , B036
Open AccessAbstract B036: Treatment modalities in KRAS-driven cancer
KRAS is the most common RAS isoform, found to be altered in 22% of RAS-mutated cancers. The mutant protein is found most prevalently in pancreatic cancer followed by colorectal, non-small cell lung cancer and other solid tumors. Due to its structural complexity, KRAS remained “undruggable” for several decades. Recently, the discovery of a specific protein binding pocket has led to the development of small molecule inhibitors that potently bind and inhibit KRAS downstream signalling. The accelerated FDA approval of sotorasib and adagrasib for treatment of NSCLC patients harbouring KRASG12C-mutation and further clinical evaluation of several other inhibitors of KRASG12C are under investigation, however emergence of resistance and limited efficacy beyond non-small cell lung cancer is a major concern. Targeting KRAS mutations other than KRASG12C (i.e., without a mutant-specific cysteine residue) with small molecules, has been considered much more challenging, especially for developing covalent inhibitors. Small molecule targeting of KRASG12D (e.g. MRTX1133), is under active preclinical investigation and small molecule drugs that target other KRAS-activating mutations (G12S, G12R and G12V) are being intensely explored. A variety of novel alternative approaches are also being investigated to target tumors driven by mutant KRAS, such as (i) targeting complementary signalling pathways (ii) enhancing mutant KRAS protein degradation using PROTACS, (iii) developing pan-KRAS small molecules inhibitors, (iv) anti-KRAS immune cell-based therapies, (v) small interfering RNAs to block mutant KRAS expression and (vi) anti-KRAS vaccines. Here, we aim to provide a comprehensive overview of current status and future prospect of these modalities, in the context of RAS-mutated cancers. Citation Format: Darren R. Tyson, Neetu Singh, Prashant K. Bhavar, Partha Pratim Sarma, Uday Kumar Surampudi, Sathish Katike. Treatment modalities in KRAS-driven cancer [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr B036.
- Open Access
- 2 November 2022
- Published by IntechOpen
Long Non-Coding RNA in Neural Stem Cells Self-Renewal, Neurogenesis, Gliogenesis and Synaptogenesis
Evidence reports the key roles of lncRNAs in several regulatory mechanisms of neurons and other brain cells. Neuronal lncRNAs are crucial for NSCs mediated-neuronal developmental stages like neurogenesis, neuronal differentiation, and synaptogenesis. Moreover, multilineage properties of NSCs and their association to specific cell types render them to identify the commonly accepted biomarkers for the brain. It is important to delineate the correlation between lncRNAs and NSCs fate decisions during neuronal development stages. In this review, we will summarize how NSCs fabricate embryonic tissue architecture of the central nervous system (CNS) and act as residuum in subventricular zone (SVZ) nearby the lateral wall of the lateral ventricles and the subgranular zone (SGZ) of hippocampus dentate gyrus (DG) of the adult brain. Additionally, describe the roles and molecular mechanisms of lncRNAs involved in NSCs self-renewal, neurogenesis, gliogenesis and synaptogenesis over the course of neural development. This will help us to better understand neuronal physiology.
- 2 November 2022
- Published by IntechOpen
Open AccessLong Non-Coding RNA in Neural Stem Cells Self-Renewal, Neurogenesis, Gliogenesis and Synaptogenesis
Evidence reports the key roles of lncRNAs in several regulatory mechanisms of neurons and other brain cells. Neuronal lncRNAs are crucial for NSCs mediated-neuronal developmental stages like neurogenesis, neuronal differentiation, and synaptogenesis. Moreover, multilineage properties of NSCs and their association to specific cell types render them to identify the commonly accepted biomarkers for the brain. It is important to delineate the correlation between lncRNAs and NSCs fate decisions during neuronal development stages. In this review, we will summarize how NSCs fabricate embryonic tissue architecture of the central nervous system (CNS) and act as residuum in subventricular zone (SVZ) nearby the lateral wall of the lateral ventricles and the subgranular zone (SGZ) of hippocampus dentate gyrus (DG) of the adult brain. Additionally, describe the roles and molecular mechanisms of lncRNAs involved in NSCs self-renewal, neurogenesis, gliogenesis and synaptogenesis over the course of neural development. This will help us to better understand neuronal physiology.